Guerbet

Guerbet: 2021 revenue

10 Feb 2022 08:54:31 By Nasdaq GlobeNewswire

Guerbet: 2021 Corporate Social Responsibility Gaïa-Index: Guerbet consolidates its position as leader in the “Healthcare” category

04 Jan 2022 09:02:01 By Nasdaq GlobeNewswire

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

13 Dec 2021 22:00:00 By Nasdaq GlobeNewswire

Guerbet: Revenue at September 30, 2021

21 Oct 2021 08:46:04 By Nasdaq GlobeNewswire

Guerbet: Guerbet contributes to the NH TherAguix IPO on Euronext Growth, a specialist in innovative biotechnologies for precision radiotherapy

29 Sep 2021 09:00:54 By Nasdaq GlobeNewswire

Guerbet: 2021 half-year results

22 Sep 2021 08:54:05 By Nasdaq GlobeNewswire

Guerbet: Revenue at June 30, 2021

22 Jul 2021 08:46:33 By Nasdaq GlobeNewswire

Marc Massiot appointed to Guerbet’s Board of Directors

31 May 2021 09:00:00 By Nasdaq GlobeNewswire

Guerbet: Q1 2021 revenue

22 Apr 2021 08:45:00 By Nasdaq GlobeNewswire

Guerbet: Additional information related to 2021 financial outlook

28 Mar 2021 23:25:59 By Nasdaq GlobeNewswire

Guerbet: 2020 annual results

24 Mar 2021 09:45:00 By Nasdaq GlobeNewswire

Guerbet: Gadopiclenol - positive results for Phase III clinical trials

24 Mar 2021 00:00:00 By Nasdaq GlobeNewswire

Guerbet: Revenue 2020

11 Feb 2021 08:45:00 By Nasdaq GlobeNewswire